(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.88%.
Lexeo Therapeutics's earnings in 2026 is -$104,966,000.On average, 12 Wall Street analysts forecast LXEO's earnings for 2026 to be -$113,159,552, with the lowest LXEO earnings forecast at -$168,805,090, and the highest LXEO earnings forecast at -$78,935,794. On average, 8 Wall Street analysts forecast LXEO's earnings for 2027 to be -$99,510,922, with the lowest LXEO earnings forecast at -$135,902,403, and the highest LXEO earnings forecast at -$58,243,887.
In 2028, LXEO is forecast to generate -$89,708,724 in earnings, with the lowest earnings forecast at -$97,277,509 and the highest earnings forecast at -$80,468,528.